Tislelizumab (Clinical Trials and Efficacy)
Clinical trials have demonstrated the efficacy of tislelizumab in improving overall survival and progression-free survival in patients with advanced cancers. Studies have shown promising results, particularly in patients who have not responded well to other treatments. The safety profile of tislelizumab is consistent with other PD-1 inhibitors, with common side effects including fatigue, rash, pruritus, and immune-related adverse events such as colitis and hepatitis.